Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

And with that, they were able to apply that to thinking about how to rebuild the post-COVID revenue profile for the company." ...

Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.

Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (NYSE: PFE). It reported third-quarter ...

Cheng Xin / Getty Images Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

A significant focus of Starboard’s critique lies in Pfizer’s investment in external innovation. The company has spent nearly $70 billion on M&A since 2022, including high-profile deals like ...

If those two high-profile products are taken out ... This meant a pair of convincing beats for the company. On average, analysts following Pfizer were expecting less than $15 billion for sales ...